Azitra Receives FDA Fast Track Designation for ATR-04, Stock Up 10.5%

Sep 18, 2024, 01:02 PM

Azitra, Inc. has received Fast Track designation from the FDA for its drug ATR-04, aimed at treating skin rash caused by EGFR inhibitors. This designation is expected to expedite the development and review process of ATR-04. The company's stock (AZTR) saw a 10.5% increase in pre-market trading following the announcement.